Researchers have discovered a co-aggregation between amyloid beta and the protein medin in the brains of those with Alzheimer's disease.
Lecanemab, an amyloid-clearing monoclonal antibody drug shows positive results in the treatment of Alzheimer's disease. The drug is now poised for FDA approval early in 2023. Lecanemab slows cognitive decline by 27%.
The brains of older, cognitively healthy people have similar amounts of dissolvable, non-fibrilla amyloid proteins as the brains of those with Alzheimer's disease. Findings challenge the long-standing theory that having higher levels of amyloid proteins is an underlying cause of Alzheimer's disease.
Samples of brain tissue from those with Alzheimer's revealed marked changes in potassium isotopes that correlated with amyloid-beta accumulation.
Study provides experimental evidence of an alternative binding site on amyloid-beta aggregates. The discovery opens the door to the development of new therapies for Alzheimer's disease.
Researchers discovered a correlation between obesity-related neurodegeneration and Alzheimer's disease pathology. Losing weight, they say, can slow age-related cognitive decline and reduce the risk of developing Alzheimer's.
A new method dubbed STARmap PLUS was utilized to track and map changes in tau and amyloid beta in the brain as Alzheimer's disease progressed in mouse models.
